DOP2011000285A - 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso - Google Patents

2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso

Info

Publication number
DOP2011000285A
DOP2011000285A DO2011000285A DO2011000285A DOP2011000285A DO P2011000285 A DOP2011000285 A DO P2011000285A DO 2011000285 A DO2011000285 A DO 2011000285A DO 2011000285 A DO2011000285 A DO 2011000285A DO P2011000285 A DOP2011000285 A DO P2011000285A
Authority
DO
Dominican Republic
Prior art keywords
acetamido
substituted
triazolons
aril
prevention
Prior art date
Application number
DO2011000285A
Other languages
English (en)
Inventor
Jorg Keldenich
Elisabeth Pook
Ulf Bruggemeier
Peter Kolkhof
Chantal Furstner
Armin Kern
Volker Geiss
Martina Delbeck
Axel Kretschmer
Carsten Schmeck
Hubert Trubel
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of DOP2011000285A publication Critical patent/DOP2011000285A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70One oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/29Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/14Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • C07D233/36One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • C07D263/22Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solìcitud se refiere a nuevas 2-acetamido-5-aril-1,2,4-triazolonas sustituidas, a procedimientos para su preparación, a su uso solas o en combinaciones para el tratamiento y/o la prevención de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la prevención de enfermedades, en particular para el tratamiento y/o la prevención de enfermedades cardiovasculares.
DO2011000285A 2009-03-18 2011-09-13 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso DOP2011000285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009013640 2009-03-18
DE102010001064A DE102010001064A1 (de) 2009-03-18 2010-01-20 Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung

Publications (1)

Publication Number Publication Date
DOP2011000285A true DOP2011000285A (es) 2011-12-15

Family

ID=42629029

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2011000285A DOP2011000285A (es) 2009-03-18 2011-09-13 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso

Country Status (34)

Country Link
US (2) US8202895B2 (es)
EP (1) EP2408751B1 (es)
JP (1) JP5849043B2 (es)
KR (1) KR20110128206A (es)
CN (2) CN103864704A (es)
AR (1) AR075868A1 (es)
AU (1) AU2010225170B2 (es)
BR (1) BRPI1009481A2 (es)
CA (1) CA2755641C (es)
CL (1) CL2011002255A1 (es)
CO (1) CO6440531A2 (es)
CR (1) CR20110485A (es)
CU (2) CU24085B1 (es)
DE (1) DE102010001064A1 (es)
DO (1) DOP2011000285A (es)
EA (1) EA023694B1 (es)
EC (1) ECSP11011320A (es)
ES (1) ES2648871T3 (es)
GT (1) GT201100239A (es)
HK (2) HK1167864A1 (es)
HN (1) HN2011002406A (es)
IL (2) IL214614A0 (es)
MA (1) MA33123B1 (es)
MX (1) MX2011009539A (es)
MY (1) MY156777A (es)
NZ (1) NZ595207A (es)
PE (1) PE20120656A1 (es)
SG (2) SG10201401415QA (es)
SV (1) SV2011004019A (es)
TN (1) TN2011000466A1 (es)
TW (1) TW201100392A (es)
UA (1) UA108198C2 (es)
UY (1) UY32497A (es)
WO (1) WO2010105770A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006024024A1 (de) * 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009028929A1 (de) * 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
BR112012021498B8 (pt) 2010-02-27 2020-04-14 Bayer Ip Gmbh ariltriazolonas ligadas a bisaril e seu uso
DE102010040187A1 (de) * 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
EP3197891B1 (de) 2014-09-24 2018-11-21 Bayer Pharma Aktiengesellschaft Faktor xia hemmende pyridobenzazepin- und pyridobenzazocin-derivate
TWI694072B (zh) 2014-11-03 2020-05-21 德商拜耳製藥股份有限公司 經羥烷基取代之苯基三唑衍生物及其用途
EP3452472A1 (en) 2016-05-03 2019-03-13 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
EP3452469A1 (en) 2016-05-03 2019-03-13 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
WO2017191107A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted phenyltriazole derivatives and uses thereof
US10800746B2 (en) 2016-05-03 2020-10-13 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
UY37222A (es) * 2016-05-03 2017-11-30 Bayer Pharma AG PROCEDIMIENTO PARA LA PREPARACIÓN DE DERIVADOS DE 1-FENILO-1,2,4-TRIAZOL SUSTITUIDOS POR 5-HIdroxIalQUILO
WO2018011017A1 (de) 2016-07-11 2018-01-18 Bayer Pharma Aktiengesellschaft 7-substituierte 1-pyridyl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190045A1 (ar) 2016-09-14 2019-03-14 Bayer Ag مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها.
EP3296298A1 (de) 2016-09-14 2018-03-21 Bayer Pharma Aktiengesellschaft 7-substituierte 1-aryl-naphthyridin-3-carbonsäureamide und ihre verwendung
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EP3529244A1 (en) 2016-10-20 2019-08-28 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
US11173151B2 (en) 2017-10-24 2021-11-16 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
UA126456C2 (uk) 2017-10-24 2022-10-05 Баєр Акціенгезельшафт Проліки заміщених триазольних похідних та їх застосування
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
EP3700898A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3084411A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700903A1 (de) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituierte imidazopyridinamide und ihre verwendung
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3553082A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Brain natriuretic peptide engrafted antibodies
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
EP3553081A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Atrial natriuretic peptide engrafted antibodies
JOP20200287A1 (ar) 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
SG11202010679SA (en) 2018-05-17 2020-11-27 Bayer Ag Substituted dihydropyrazolo pyrazine carboxamide derivatives
WO2020216669A1 (de) 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Phenylsubstituierte imidazopyridinamide und ihre verwendung
WO2021094210A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
WO2021094208A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted imidazo pyrimidine ep3 antagonists
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
EP3822265A1 (en) 2019-11-15 2021-05-19 Bayer AG Substituted hydantoinamides as adamts7 antagonists
EP3822268A1 (en) 2019-11-15 2021-05-19 Bayer Aktiengesellschaft Substituted hydantoinamides as adamts7 antagonists
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
CA3204596A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
WO2022122916A1 (en) 2020-12-10 2022-06-16 Bayer Aktiengesellschaft Substituted pyrazolyl piperidine carboxylic acids
PE20231501A1 (es) 2020-12-10 2023-09-26 Bayer Ag Acidos pirazol piperidin carboxilicos sustituidos
EP4011874A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
TW202412753A (zh) 2022-06-09 2024-04-01 德商拜耳廠股份有限公司 用於治療女性心臟衰竭合併保留射出分率的可溶性鳥苷酸環化酶活化劑

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
EP0412594B1 (en) 1989-07-28 1996-01-03 Merck & Co. Inc. Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
IL98167A0 (en) * 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0586513A1 (en) 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
IT1251488B (it) 1991-09-17 1995-05-15 Mini Ricerca Scient Tecnolog Ossa(tia)diazol- e triazol-oni(tioni) ad attivita' acaricida ed insetticida
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
JP3951342B2 (ja) * 1996-07-10 2007-08-01 味の素株式会社 新規アスパルチルジペプチドアミド誘導体及び甘味剤
SK9162000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
ES2237141T3 (es) 1998-07-24 2005-07-16 Bayer Cropscience Ag Benzoilciclohexanodionas substituidas.
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
PL373300A1 (en) * 2001-03-28 2005-08-22 Bristol-Myers Squibb Company Novel tyrosine kinase inhibitors
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2004221891B2 (en) 2003-03-14 2009-11-19 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin CGRP receptor antagonists
KR20060066141A (ko) 2003-06-27 2006-06-15 버글린 코퍼레이션 오브 워싱턴 사과 및 연한 코아를 가지거나 피트를 가진 다른 과일들을작은 응력을 가지고 정확하게 코아제거하고슬라이스절단하기 위한 기계
WO2005086836A2 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
CN1933832A (zh) 2004-03-08 2007-03-21 惠氏公司 离子通道调节剂
DE102004017627A1 (de) 2004-04-10 2005-10-27 Bayer Healthcare Ag Verwendung von vollen 5-HT1A-Agonisten zur Hemmung der opiat/opioid-induzierten Atemdepression
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2006066133A2 (en) 2004-12-16 2006-06-22 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
WO2008052031A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102009028929A1 (de) * 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
BR112012021498B8 (pt) * 2010-02-27 2020-04-14 Bayer Ip Gmbh ariltriazolonas ligadas a bisaril e seu uso

Also Published As

Publication number Publication date
GT201100239A (es) 2013-08-21
ES2648871T3 (es) 2018-01-08
US8796324B2 (en) 2014-08-05
AU2010225170A1 (en) 2011-10-13
US20100261771A1 (en) 2010-10-14
HK1199031A1 (en) 2015-06-19
IL241360A0 (en) 2015-11-30
AU2010225170B2 (en) 2015-08-06
MA33123B1 (fr) 2012-03-01
CO6440531A2 (es) 2012-05-15
CN103864704A (zh) 2014-06-18
CU20140141A7 (es) 2015-08-27
EP2408751B1 (de) 2017-08-23
US8202895B2 (en) 2012-06-19
CR20110485A (es) 2012-01-31
CA2755641C (en) 2017-06-27
HN2011002406A (es) 2015-02-09
TW201100392A (en) 2011-01-01
SG174332A1 (en) 2011-11-28
DE102010001064A1 (de) 2010-09-23
CU20110174A7 (es) 2012-02-15
JP2012520835A (ja) 2012-09-10
PE20120656A1 (es) 2012-05-27
CA2755641A1 (en) 2010-09-23
SG10201401415QA (en) 2014-08-28
EA023694B1 (ru) 2016-07-29
EA201190217A1 (ru) 2012-04-30
BRPI1009481A2 (pt) 2016-03-01
IL214614A0 (en) 2011-09-27
CU24085B1 (es) 2015-03-30
CL2011002255A1 (es) 2012-04-09
TN2011000466A1 (en) 2013-03-27
MY156777A (en) 2016-03-31
SV2011004019A (es) 2011-12-15
UY32497A (es) 2010-10-29
US20120238607A1 (en) 2012-09-20
HK1167864A1 (en) 2012-12-14
CN102438990A (zh) 2012-05-02
AR075868A1 (es) 2011-05-04
EP2408751A1 (de) 2012-01-25
MX2011009539A (es) 2012-02-21
UA108198C2 (uk) 2015-04-10
JP5849043B2 (ja) 2016-01-27
ECSP11011320A (es) 2011-10-31
NZ595207A (en) 2014-02-28
CN102438990B (zh) 2014-08-20
WO2010105770A1 (de) 2010-09-23
KR20110128206A (ko) 2011-11-28

Similar Documents

Publication Publication Date Title
DOP2011000285A (es) 2-acetamido-5-aril-1, 2, 4-triazolonas sustituidas y su uso
ECSP12012310A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY31228A1 (es) Ariloxazoles sustituidos y su uso
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
ECSP14013224A (es) Pirimidinas anilladas sustituidas y uso de las mismas
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
ECSP10010711A (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CU20100183A7 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CU20100260A7 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
CR10449A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
HN2008000946A (es) Nuevos derivados de furopirimidina aciclicos sustituidos